U.S. authorities accuse the two top officials of CANARX, a Canadian company, of running a long-running scheme to illegally import prescription drugs into the United States, according to court records filed Tuesday.

John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges, the records show. The arrest warrant also charges him with introducing misbranded drugs into interstate commerce and illegal drug importation. No plea has been filed.

Bob Howard, his brother and the company's president and a director, is also wanted in the federal investigation. He has not yet been taken into custody, according to an affidavit from Dustin Dobbs, a special agent with the Food and Drug Administration's Office of Criminal Investigations.

The affidavit states that the FDA found "there is probable cause to believe that (CANARX) illegally imported or caused the illegal importation of prescription drugs into the United States …." It does not specify which medications were involved. The complaint covers February 22, 2017, through April 15, 2026.

CANARX, founded in 2002 and based in Windsor, Ontario, describes itself on its website as the first international prescription provider for the U.S. The company said it sources medications from Canada, the United Kingdom, Australia and New Zealand.

The company's general counsel, Joseph Morris, told CNBC in a statement: "The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court."

The FDA has scrutinized the company for years. In 2019, the agency sent CANARX a warning letter saying it was operating "in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs." In 2023, the agency seized medication the company was shipping that it said was potentially misbranded and counterfeit, according to an email to a patient that CNBC obtained.

Separately, Gilead Sciences has a pending civil lawsuit accusing CANARX and other companies of illegally importing Biktarvy, its HIV medication. A Gilead spokesperson said the company "has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain." CANARX has not responded to that lawsuit.